Pfizer announced this week that it has started trials on a drug that could offer a vital new tool for combatting the pandemic.
According to the company, the trial will test the treatment — currently dubbed PF-07321332 — on 2,660 healthy participants who live with someone who has tested positive for the virus and is showing symptoms. The drug is designed to work by blocking an enzyme involved in virus replication, and is being tested in combination with ritonavir, an antiretroviral protease inhibitor often used alongside HIV treatments.
Pfizer says that it developed the drug as an oral treatment so that it can be administered quickly in the event of virus exposure.
Read the full Reuters report.
